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froOBJECTIVES The purpose of this study was to characterize outcomes for everolimus-eluting stent (EES)–treated
subjects according to treatment with continued thienopyridine plus aspirin versus aspirin alone 12 to 30 months
after stenting.
BACKGROUND In the DAPT (Dual Antiplatelet Therapy) study, continued thienopyridine plus aspirin beyond 1 year
after coronary stenting reduced ischemic events. Given low rates of stent thrombosis and myocardial infarction (MI)
for current drug-eluting stents, we examined outcomes among EES-treated subjects in the DAPT study.
METHODS The DAPT study enrolled 25,682 subjects (11,308 EES-treated) after coronary stenting. Following 12 months
of treatment with thienopyridine and aspirin, eligible subjects continued treatment with aspirin and 9,961 (4,703 with
EES) were randomized to 18 months of continued thienopyridine or placebo. Stent type was not randomized, and the
EES subset analysis was post hoc.
RESULTS Among EES-treated patients, continued thienopyridine reduced stent thrombosis (0.3% vs. 0.7%, hazard
ratio [HR]: 0.38, 95% conﬁdence interval [CI]: 0.15 to 0.97; p ¼ 0.04) and MI (2.1% vs. 3.2%, HR: 0.63, 95% CI: 0.44 to
0.91; p ¼ 0.01) versus placebo but did not reduce a composite of death, MI, and stroke (4.3% vs. 4.5%, HR: 0.89, 95%
CI: 0.67 to 1.18; p ¼ 0.42), and increased moderate/severe bleeding (2.5% vs. 1.3%, HR: 1.79, 95% CI: 1.15 to 2.80;
p ¼ 0.01), and death (2.2% vs. 1.1%, HR: 1.80, 95% CI: 1.11 to 2.92; p ¼ 0.02). Death due to cancer and not related to
bleeding was increased (0.64% vs. 0.17%; p ¼ 0.01).
CONCLUSIONS In EES-treated subjects, signiﬁcant reductions in stent thrombosis and MI and an increase in bleeding
were observed with continued thienopyridine beyond 1 year compared with aspirin alone. (The Dual Antiplatelet
Therapy Study [DAPT Study]); NCT00977938) (J Am Coll Cardiol Intv 2016;9:138–47) © 2016 by the American College
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139AB BR E V I A T I O N S
AND ACRONYM S
BMS = bare-metal stent(s)
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
HR = hazard ratio
MACCE = major adverse
cardiovascular and
cerebrovascular events
MI = myocardial infarctionI n the DAPT (Dual Antiplatelet Therapy) study,patients who were free from major ischemic orbleeding events at 1 year after coronary stenting
(either drug-eluting stents [DES] or bare-metal stents
[BMS]), experienced signiﬁcant reductions in stent
thrombosis and myocardial infarction (MI) but in-
creases in moderate or severe bleeding when treated
with 30 months of thienopyridine plus aspirin
compared with 12 months (1,2). Approved DES have
been designed with different metallic scaffold de-
signs, polymers, and eluted medications, resulting
in different effectiveness and safety outcomes in clin-
ical trials. Recent randomized trials and meta-
analysis suggest that everolimus-eluting stents
(EES), the most commonly used stent type in both
the DAPT study as well as current clinical practice,
are associated with lower rates of stent thrombosis
compared with paclitaxel-eluting stents (3–5).SEE PAGE 148Subjects treated with any DES approved and
available in the United States at the time of study
enrollment were eligible to be enrolled in the DAPT
study. Although patients were not randomized to
stent types, in adjusted analysis, there was het-
erogeneity in the relative reduction in major
adverse cardiovascular and cerebrovascular events
(MACCE) (a composite endpoint of death, MI, or
stroke) according to stent type (1), and a large
treatment beneﬁt for continued therapy was
observed among the subset of patients treated with
paclitaxel-eluting stents (n ¼ 2,666 randomized)
(6). To determine whether the results of the DAPT
study were generalizable to EES, we evaluated the
beneﬁts and risks of treatment with thienopyridine
plus aspirin for 30 versus 12 months in the
large subset of patients (11,308 enrolled, 4,703
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DESIGN. The DAPT study was a double-blind,
international, multicenter, randomized, placebo-
controlled trial designed (7) to compare 30
versus 12 months of aspirin plus thienopyr-
idine therapy (clopidogrel or prasugrel) after
coronary stenting with either DES or BMS
(NCT00977938). Randomization was stratiﬁed
by DES/BMS, hospital site, subject complex-
ity, and thienopyridine drug type. The results
comparing randomized treatments among
DES- (1) and BMS-treated (2) cohorts on is-
chemic and bleeding endpoints, as well as
comparing BMS- versus DES-treated patients
on these endpoints (8), have been reported. The insti-
tutional review board at each participating institution
approved the study, and each participant provided
written, informed consent.
The primary study analysis within all randomized
DES-treated patients compared randomized treat-
ments with respect to the primary effectiveness end-
points of stent thrombosis and MACCE from 12 to 30
months post-procedure and the primary safety
endpoint of moderate or severe bleeding from 12 to
30 months post-procedure (1). DES types included EES
(Xience, Abbott Vascular, Santa Clara, California;
PROMUS, Boston Scientiﬁc, Marlborough, Massachu-
setts), sirolimus-eluting stents (Cypher, Cordis,
Bridgewater, New Jersey), zotarolimus-eluting stents
(Endeavor, Medtronic, Minneapolis, Minnesota), and
paclitaxel-eluting stents (TAXUS, Boston Scientiﬁc,
Marlborough, Massachusetts). Although stent type
among various DES was not randomized, assessments
of randomized treatment-by-DES type interactions on
stent thrombosis and MACCE were pre-speciﬁed to
determine whether the randomized treatment effect
was consistent across DES types. Although random-
ized treatment effect on stent thrombosis did not varyand Company, Abbott, Biotronik, Boston Scientiﬁc,
rom Sanoﬁ and Servier; is a consultant for Amarin,
ng, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Janssen,
r, and The Medicines Company; and is a stockholder
onsultant for Gilead Sciences, Boston Scientiﬁc, and
a, Daiichi-Sankyo, Medtronic, Abbott Vascular, and
bott Vascular; and receives speaking honoraria from
) from Medtronic, Boston Scientiﬁc, and Celonova.
for statistical services for the paper. Dr. Mauri has
Medtronic, Eli Lilly and Company, Daiichi-Sankyo,
ultant for Amgen, Medtronic, Eli Lilly and Company,
m AstraZeneca and Sanoﬁ. Drs. Kereiakes and Hsieh
is paper to disclose.
mber 29, 2015, accepted October 1, 2015.
FIGURE 1 Subject Flowchart
Patients were enrolled within 72 h after stent placement and were followed for 12 months while they received open-label treatment with thienopyridine plus aspirin. At
12 months, they were randomly assigned to receive thienopyridine or placebo (each in addition to aspirin) for another 18 months. Although the number of patients with
available data on clinical follow-up is reported in each group, the efﬁcacy endpoints were analyzed with the last available follow-up information in the intention-to-treat
population. Among the 4,703 randomized patients, at least 30 months of clinical follow-up was complete in 2,227 (95.0%) versus 2,242 (95.1%) subjects and clinical
follow-up or vital status was available in 2,233 (95.2%) versus 2,247 (95.3%) of patients receiving continued thienopyridine or placebo, respectively. *Subjects may have
>1 event. **Site terminated participation, randomization target met prior to subject follow-up, or subject not recognized to be eligible by site. †Subjects moved, were
incarcerated, or were prematurely exited from the study. DES ¼ drug-eluting stent(s); EES ¼ everolimus-eluting stent(s); GUSTO ¼ Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Arteries.
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140by stent type (interaction p ¼ 0.76), variation in treat-
ment effect on MACCE was observed (interaction p ¼
0.048) (1). The current analysis was performed among
randomized subjects treated only with EES to deter-
mine the effects of treatment, particularly on those
endpoints that could be presumed to be stent-related
(e.g., stent thrombosis, MACCE, and MI). Secondary
endpoints included additional components of MACCE
(mortality, stroke) and GUSTO (Global Utilization of
Streptokinase and Tissue Plasminogen Activator for
Occluded Arteries) moderate or severe bleeding.
STUDY POPULATION AND PROCEDURES. Adult can-
didates for thienopyridine plus aspirin therapy who
were treated with Food and Drug Administration–
approved coronary stents were enrolled within 3 days
of stent placement. All patients received open-labelaspirin plus thienopyridine for 12 months after coro-
nary stenting, and at month 12, patients who had
tolerated DAPT without a MACCE, repeat revascular-
ization, or moderate or severe bleeding event and who
had been adherent to thienopyridine therapy (deﬁned
as having taken 80% to 120% of the drug without an
interruption of longer than 14 days) continued aspirin
and were randomized to either continued thienopyr-
idine or to placebo for a further 18 months.
Endpoint events were adjudicated by a clinical
events committee administered by the Harvard Clin-
ical Research Institute and blinded to treatment
assignment, as previously described (7). Deaths were
classiﬁed as cardiac, vascular, or noncardiovascular,
according to the Academic Research Consortium deﬁ-
nition (9). Cardiovascular procedure-related bleeding
TABLE 1 Baseline Characteristics of All Randomized Subjects
Treated With Everolimus-Eluting Stents
Continued
Thienopyridine
(n ¼ 2,345)
Placebo
(n ¼ 2,358)
p
Value
Demographics
Age, yrs 62.6  10.1 62.0  10.1 0.052
Female 1,774 (24.4) 1,787 (24.2) 0.92
Non-white race* 207 (9.0) 192 (8.4) 0.43
Hispanic or Latino
ethnic group*
54 (2.4) 63 (2.7) 0.45
Weight, kg 90.9  19.2 91.2  18.8 0.64
BMI, kg/m2 30.2  5.6 30.4  5.6 0.33
Medical history
Diabetes mellitus 671 (28.8) 670 (28.5) 0.87
Hypertension 1,734 (74.3) 1,705 (72.5) 0.18
Cigarette smoker 528 (22.9) 522 (22.5) 0.75
Stroke/TIA 95 (4.1) 97 (4.1) 0.94
Congestive heart failure 83 (3.6) 91 (3.9) 0.59
Peripheral arterial disease 112 (4.9) 114 (5.0) 0.95
Prior PCI 693 (29.8) 672 (28.6) 0.39
Prior CABG 250 (10.7) 256 (10.9) 0.85
Prior MI 503 (21.9) 459 (19.9) 0.10
Indication for index procedure
Acute coronary syndromes 652 (27.8) 620 (26.3) 0.25
STEMI 258 (11.0) 241 (10.2) 0.39
NSTEMI 394 (16.8) 379 (16.1) 0.50
Unstable angina† 285 (12.2) 298 (12.6) 0.63
Stable angina 960 (40.9) 954 (40.5) 0.74
Other 448 (19.1) 486 (20.6) 0.20
Region 1.00
North American 1,922 (82.0) 1,932 (81.9)
Europe 308 (13.1) 309 (13.1)
Australia/New Zealand 115 (4.9) 117 (5.0)
Any risk factor for stent
thrombosis
STEMI or NSTEMI 652 (27.8) 620 (26.3) 0.25
Renal insufﬁciency/failure 98 (4.2) 83 (3.5) 0.26
LVEF <30% 32 (1.5) 34 (1.6) 0.81
$2 vessels stented 10 (0.4) 10 (0.4) 1.00
$2 lesions/vessel 38 (1.6) 36 (1.5) 0.82
Lesion length $30 mm 192 (8.2) 190 (8.1) 0.87
Bifurcation lesion 178 (7.6) 187 (8.0) 0.70
In-stent restenosis 66 (2.8) 71 (3.0) 0.73
Vein bypass graft stented 53 (2.3) 51 (2.2) 0.84
Unprotected left main
stented
8 (0.3) 8 (0.3) 1.00
Thrombus-containing
lesion
215 (11.3) 183 (9.5) 0.06
Prior brachytherapy 6 (0.3) 4 (0.2) 0.55
Thienopyridine at
randomization
1.00
Clopidogrel 1,979 (84.4) 1,989 (84.4)
Prasugrel 366 (15.6) 369 (15.7)
No. of treated lesions 1.3  0.5 1.3  0.5 0.20
No. of treated vessels 1.1  0.3 1.1  0.3 0.81
No. of stents 1.5  0.8 1.4  0.7 0.20
Minimum stent diameter 0.52
<3 mm 1,101 (47.0) 1,085 (46.0)
$3 mm 1,244 (53.1) 1,273 (54.0)
Continued in the next column
TABLE 1 Continued
Continued
Thienopyridine
(n ¼ 2,345)
Placebo
(n ¼ 2,358)
p
Value
Total stent length, mm 27.2  16.3 26.9  16.3 0.51
Lesion(s)
Treated vessel‡
Native coronary 2,969 (97.6) 2,946 (98.0) 0.29
Left main 22 (0.7) 28 (0.9) 0.40
Left anterior
descending
1,292 (42.5) 1,282 (42.7) 0.90
Right 985 (32.4) 930 (30.9) 0.24
Circumﬂex 670 (22.0) 706 (23.5) 0.18
Venous graft 64 (2.1) 55 (1.8) 0.46
Arterial graft 9 (0.3) 5 (0.2) 0.42
In-stent restenosis 121 (4.0) 124 (4.1) 0.78
Extreme tortuosity 134 (4.4) 121 (4.1) 0.46
Heavy calciﬁcation 277 (9.2) 256 (8.6) 0.44
Modiﬁed ACC/AHA
lesion class B2 or C
1,299 (45.2) 1,271 (44.9) 0.83
Values are mean  SD or n (%). *Race and ethnic group were self-reported. †This
category included unstable angina without reported elevation of cardiac enzymes.
‡A total of 3,043 lesions were treated in subjects randomized to continued thie-
nopyridine and 3,007 in subjects randomized to placebo.
ACC¼American College of Cardiology; AHA¼AmericanHeart Association; BMI¼
body mass index; CABG ¼ coronary bypass artery graft; LVEF ¼ left ventricular
ejection fraction; MI ¼myocardial infarction; NSTEMI¼ non–ST-segment elevation
myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼
ST-segment elevation myocardial infarction; TIA ¼ transient ischemic attack.
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141or bleeding related to primarily cardiac or vascular
conditions was considered cardiovascular death; other
fatal bleeds were considered noncardiovascular. A
second blinded clinical events committee evaluated
the potential contribution of speciﬁc pathological
mechanisms to mortality (10). The classiﬁcation of
cardiac, vascular, and noncardiovascular death was
not readjudicated. All deathswere reviewed regardless
of initial adjudicated cause. Bleeding-related death
was adjudicated as any death that was possibly, prob-
ably, or deﬁnitely related to a prior bleeding event.
Cancer-related death was adjudicated as any death
that was possibly, probably, or deﬁnitely related to a
malignancy or complications from treatments specif-
ically administered for the malignancy. Causes of
death were not mutually exclusive, that is, a patient
could have both a bleeding- and cancer-related death.
A central data safety monitoring board and an in-
dependent biostatistician reviewed unblinded data
from all subjects at regular intervals.
STATISTICAL ANALYSIS. All analyses were per-
formed on the subset of all randomized EES-treated
patients, according to the intention-to-treat princi-
ple. Analysis of the interaction of stent type
and treatment assignment (duration of antiplatelet
therapy) on the outcomes of stent thrombosis,
MACCE, and GUSTO severe or moderate bleeding was
FIGURE 2 Cumulative Incidence of Stent Thrombosis, MACCE, a Myocardial Infarction, and GUSTO Moderate/Severe Bleeding According
to Randomized Treatment Arm
No. At Risk
Continued 
Thienopyridine 
2345 2299 2272 2255 2222 2181 2160
Placebo 2358 2314 2285 2263 2232 2213 2187
12-30 Months:
HR 0.38 (0.15-0.97)
0.3% vs.0.7%
P=0.04 
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No. At Risk
Continued 
Thienopyridine 
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12-30 Months:
HR 0.89 (0.67-1.18)
4.3% vs. 4.5%
P=0.42
Continued Thienopyridine  
Placebo 
5%
4%
3%
2%
1%
0%
12 15 18 21 24 27 30
Months After Randomization
A
B
Kaplan-Meier curves are shown for the endpoints of Academic Research Consortium deﬁnite or probable stent thrombosis (A), major adverse
cardiovascular and cerebrovascular events (MACCE) (B), myocardial infarction (C), and GUSTO (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Arteries) moderate/severe bleeding (D) in all randomized subjects treatedwith everolimus-eluting stents (n¼
4308) at 12 to 30 months, according to randomized treatment arm (continued thienopyridine vs. placebo). Hazard ratios (HRs) for continued
thienopyridine vs. placebo and corresponding Cox regression p values are presented. The number at riskwas deﬁned as the number of patients who
had not had the event of interest and who were available for subsequent follow-up. *HR for continued thienopyridine versus placebo.
Continued on the next page
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142pre-speciﬁed, as previously described. The Cox pro-
portional hazards assumption was met for these
endpoints for the primary DES cohort and for the
EES-treated subset. All other within-subset analyses
(i.e., comparing randomized treatment arms within
EES-treated subjects) were not pre-speciﬁed.Kaplan-Meier estimates of endpoint events were
calculated for each treatment group. For the out-
comes of stent thrombosis, MACCE, death, MI, and
GUSTO severe or moderate bleeding, hazard ratios
(HRs) and 95% conﬁdence intervals (CIs) were
adjusted for baseline characteristics; adjusted Cox
FIGURE 2 Continued
No. At Risk
Continued 
Thienopyridine 
2345 2290 2256 2232 2193 2147 2124
Placebo 2358 2314 2282 2257 2223 2201 2174
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No. At Risk
Continued 
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143proportional hazard regression p values were used to
compare the treatment difference and to assess ran-
domized treatment by DES type interaction effects.
For all other outcomes, HRs and 95% CIs were strat-
iﬁed by randomization strata. Kaplan-Meier esti-
mates were compared between treatment groups
using a log-rank p value stratiﬁed by randomization
strata.
For baseline characteristics, continuous variables
were compared using the Student 2-sample t test;
categorical parameters were compared using the chi-
square test or Fisher exact test as appropriate.All statistical analyses were conducted at the Har-
vard Clinical Research Institute with the use of SAS
software, version 9.2. (SAS Institute Inc., Cary, North
Carolina). The authors (L.M., J.M.M.) had full access
to the data and vouch for the integrity of the analyses
presented.
RESULTS
STUDY POPULATION. Of 25,682 patients enrolled
in the DAPT study, 11,308 received an EES. Of 11,648
randomized patients, 9,961 received a DES at the index
FIGURE 3 Outcomes (12 to 30 Months) in Randomized Patients According to Treatment Arm
(A) All randomized EES-treated patients; (B) all randomized DES-treated patients. Percentages are Kaplan-Meier estimates. (HRs), conﬁdence
intervals (CIs), and p values are adjusted for baseline characteristics as listed in the supplemental appendix of Mauri et al. (1). Stent thrombosis
includes Academic Research Consortium deﬁnite/probable deﬁnitions. Bleeding severity includes GUSTO moderate or severe deﬁnitions.
MACCE ¼ major adverse cardiovascular and cerebrovascular events; other abbreviations as in Figures 1 and 2.
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144procedure, with the following stent types: everolimus
alone (4,703 [47.2%]), paclitaxel alone (2,666 [26.8%]),
zotarolimus alone (1,264 [12.7%]), sirolimus alone
(1,118 [11.2%]), and more than 1 type of DES (210
[2.1%]). The Taxus Liberté study, in which all patients
received a paclitaxel-eluting stent and prasugrel,
contributed 2,191 (31.5%) of the 6,945 patients treated
with a non-EES stent in the DAPT study (6). During
the open-label period, 11.2% of EES-treated patients
and 12.5% of patients treated with other DES had
events rendering them ineligible for randomization
at 12 months (p ¼ 0.003) (Online Table 1). Among 4,703randomized EES patients, at least 30 months of
clinical follow-up was complete in 2,227 (95.0%)
versus 2,242 (95.1%) patients (Figure 1) and clinical
follow-up or vital status was available in 2,233 (95.2%)
versus 2,247 (95.3%) of patients receiving continued
thienopyridine or placebo, respectively. Within EES-
treated patients, there were no signiﬁcant differ-
ences between randomized groups on baseline
characteristics except that those randomized to
continued thienopyridine were slightly older (Table 1).
As expected due to lack of randomization to stent
type, EES-treated subjects differed from patients
TABLE 2 Outcomes in All Randomized Subjects Treated With Everolimus-Eluting Stents
by Treatment Arm
Continued Thienopyridine
(n ¼ 2,345)
Placebo
(n ¼ 2,358)
Hazard Ratio
(95% CI)
p
Value
Stent thrombosis 6 (0.3) 16 (0.7) 0.38 (0.15–0.97)* 0.04†
ARC deﬁnite 5 (0.2) 12 (0.5) 0.40 (0.14–1.14) 0.08
ARC probable 1 (0.1) 4 (0.2) 0.25 (0.03–2.26) 0.18
MACCE (death, MI, stroke) 97 (4.3) 103 (4.5) 0.89 (0.67–1.18)* 0.42†
Death 49 (2.2) 26 (1.1) 1.80 (1.11–2.92)* 0.02†
Cardiovascular 23 (1.0) 18 (0.8) 1.42 (0.75–2.69) 0.28
Noncardiovascular 26 (1.2) 8 (0.4) 3.46 (1.49–8.04) 0.002
MI 48 (2.1) 72 (3.2) 0.63 (0.44–0.91)* 0.01†
Stent thrombosis-related 5 (0.2) 15 (0.7) 0.32 (0.12–0.89) 0.02
Non–stent thrombosis-
related
44 (2.0) 59 (2.6) 0.74 (0.49–1.11) 0.15
Stroke (total) 13 (0.6) 15 (0.7) 0.79 (0.36–1.75) 0.56
Ischemic 6 (0.3) 11 (0.5) 0.51 (0.17–1.49) 0.21
Hemorrhagic 7 (0.3) 3 (0.1) 1.99 (0.50–7.97) 0.32
Type uncertain 0 (0.0) 1 (0.04) 0‡ 0.33
GUSTO severe/moderate 57 (2.5) 30 (1.3) 1.79 (1.15–2.80)* 0.01†
Severe 21 (0.9) 7 (0.3) 4.01 (1.50–10.67) 0.003
Moderate 36 (1.6) 23 (1.0) 1.55 (0.89–2.69) 0.12
Values are n (%) unless otherwise indicated. Percentages are Kaplan-Meier estimates. This analysis was per-
formed on data from the period of 12 to 30 months after enrollment. Results are for all randomized patients;
patients not experiencing the endpoint were censored at 30 months or at last known follow-up, whichever was
earlier. *Hazard ratios and 95% CIs adjusted for baseline characteristics. All other hazard ratios and 95% CIs are
stratiﬁed by randomization strata. †Cox regression p value (factors for adjustment are listed in the Online
Appendix). ‡Conﬁdence interval not estimable. All other p values are log-rank stratiﬁed by randomization strata.
ARC ¼ Academic Research Consortium; CI ¼ conﬁdence interval; GUSTO ¼ Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Arteries; MACCE ¼ major adverse cardiovascular and cerebro-
vascular event(s); MI ¼ myocardial infarction.
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145treated with other DES. EES patients were slightly
older (mean age 62.3 years vs. 61.2 years), had a
lower body mass index (30.3 kg/m2 vs. 30.8 kg/m2),
were more likely to be treated with clopidogrel
(84.4% vs. 48.2%) and less likely to receive prasu-
grel (15.6% vs. 51.8%), and were more likely to have
had a prior history of cancer (all p < 0.001) (Online
Table 2). Reduction in stent thrombosis (interaction
p ¼ 0.76) and MI (interaction p ¼ 0.11) with
continued thienopyridine therapy versus placebo
was consistent among all DES after adjustment for
differences in patient characteristics and type of
thienopyridine, as was the increase in bleeding
(interaction p ¼ 0.46) and mortality (interaction
p ¼ 0.17), whereas there was variation in the
magnitude of risk reduction in MACCE across stent
types (interaction p ¼ 0.048) (1).
EFFECT OF CONTINUED THIENOPYRIDINE THERAPY
AMONG EES-TREATED PATIENTS. Among EES-
treated patients randomized to continued thieno-
pyridine or placebo, continued thienopyridine
signiﬁcantly reduced the rates of stent thrombosis
(0.3% vs. 0.7%, HR: 0.38, 95% CI: 0.15 to 0.97;
p ¼ 0.04) (Figure 2A and Figure 3) and MI (2.1% vs.
3.2%, HR: 0.63, 95% CI: 0.44 to 0.91; p ¼ 0.01)
(Figure 2C) but not MACCE (4.3% vs. 4.5%, HR: 0.89,
95% CI: 0.67 to 1.19; p ¼ 0.42) (Figure 2B, Table 2).
Moderate or severe bleeding was higher with
continued thienopyridine (2.5% vs. 1.3%, HR: 1.79,
95% CI: 1.15 to 2.80; p ¼ 0.01) (Figure 2D).
MORTALITY. During the randomized treatment
period (12 to 30 months after enrollment), all-cause
mortality was 2.2% in the continued thienopyridine
arm versus 1.1% in the placebo arm (HR: 1.80, 95% CI:
1.11 to 2.91; p ¼ 0.02). There was no difference in
cardiovascular death (1.0% continued thienopyridine
vs. 0.8% placebo; HR: 1.42, 95% CI: 0.75 to 2.69;
p ¼ 0.28). A difference in noncardiovascular death
was observed (1.2% continued thienopyridine vs.
0.4% placebo; HR: 3.46, 95% CI: 1.49 to 8.04;
p ¼ 0.002). The most common noncardiovascular
condition related to mortality was cancer (n ¼ 18 vs.
n ¼ 4; p ¼ 0.002); few of these cancer-related deaths
were associated with bleeding (3 of 18 in the
continued thienopyridine arm, 0 of 4 in the placebo
arm) (Table 3). Death related to bleeding occurred in 3
of 18 total cancer-related deaths in the continued
thienopyridine arm and in 0 of 4 in the placebo arm.
Bleeding was the second most common mechanism
of death and occurred more frequently in the
continued thienopyridine group versus placebo (n ¼ 9
vs. n ¼ 2; p ¼ 0.04), yet bleeding without cancer or
trauma was infrequent (n ¼ 4 vs. n ¼ 2; p ¼ 0.45). Ofcancer-related deaths during randomized treatment,
4 were among patients diagnosed prior to enroll-
ment in the continued thienopyridine therapy arm
versus 0 in the placebo arm, the majority of which
were metastatic at the time of diagnosis.
DISCUSSION
Technological iterations in coronary DES, including
thinner struts, novel metal alloys, biocompatible
polymers, and various eluted medications, have been
associated with improved clinical outcomes following
coronary stenting. As the hazard of very late stent-
related events (>1 year) may differ between DES
types, the potential for beneﬁt (or harm) associated
with continued thienopyridine therapy beyond 1 year
may be different as well. The DAPT study allowed
operator selection from approved and available cor-
onary stents, while comparing the effect of continued
thienopyridine therapy versus placebo, on a back-
ground of aspirin and across a range of patient and
lesion types. The most commonly used DES in
contemporary interventional practice (EES) accoun-
ted for almost one-half of all DES used in the DAPT
TABLE 3 Deaths Related to Bleeding, Trauma, and Cancer, at 12 to 30 Months After Enrollment, Per Case Review/Adjudication
Continued Thienopyridine
(n ¼ 2,345)
Placebo
(n ¼ 2,358) Difference p Value
Related to bleeding, cancer, and/or trauma
All bleeding-related death 9 (0.38) 2 (0.08) 7 (0.30) 0.04
Bleeding-related death without cancer* or trauma 4 (0.17) 2 (0.08) 2 (0.09) 0.45
Bleeding-related death with cancer 3 (0.13) 0 (0.00) 3 (0.13) 0.12
Bleeding-related death with trauma 2 (0.09) 0 (0.00) 2 (0.09) 0.25
All cancer-related death 18 (0.77) 4 (0.17) 14 (0.60) 0.002
Cancer-related death without bleeding† 15 (0.64) 4 (0.17) 11 (0.47) 0.01
All trauma-related death 3 (0.13) 0 (0.00) 3 (0.13) 0.12
Trauma-related death without bleeding† 1 (0.04) 0 (0.00) 1 (0.04) 0.50
Death with any prior history of bleeding‡
Death preceded by bleeding within 30 days 7 (0.30) 4 (0.17) 3 (0.13) 0.39
Death preceded by bleeding since randomization 14 (0.60) 8 (0.34) 6 (0.26) 0.21
Values are n (%), and event rates are expressed as absolute percentages. Deaths were classiﬁed by a blinded clinical events committee according to relatedness to cancer,
trauma, and/or bleeding (not mutually exclusive). Rates in each randomized arm are percentages. *Without possible, probable, or deﬁnite cancer-related death. †Without
possible, probable, or deﬁnite bleeding-related death. ‡Deﬁned as Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, prior to death.
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146study. Although stent type was not randomized and
individual stent type subsets were neither pre-
speciﬁed nor powered to compare treatment effect,
analysis of the consistency of treatment effect was
pre-speciﬁed.
In this context, the following observations were
made. First, continued thienopyridine plus aspirin
beyond 1 year (vs. aspirin alone) signiﬁcantly reduced
the incidence of stent thrombosis and MI following
EES treatment. Second, although heterogeneity in
treatment duration beneﬁt for reduction in the com-
posite endpoint of MACCE was present for EES, this
observation appears to be in large part driven by a
greater increase in mortality with continued thieno-
pyridine therapy, while the beneﬁcial effect on MI
was consistent across stent types. Indeed, the relative
increase in mortality among EES-treated patients
receiving continued thienopyridine therapy (vs. pla-
cebo) appears to mirror the observation on mortality
for the overall DAPT DES subset. Compared with prior
trials of extended dual antiplatelet therapy, the DAPT
study has been an isolated example identifying a
relationship between mortality and continued thie-
nopyridine plus aspirin therapy (11), largely due to an
increase in noncardiovascular-related mortality. The
mortality signal in the overall DAPT study has been
analyzed after adjudication of all deaths and appears
to be related to higher rates of cancer-related death in
patients with pre-existing cancer diagnoses, and not
mainly attributable to increased bleeding risks (10).
Notably, no increase in mortality was observed in
BMS-treated patients receiving continued thienopyr-
idine therapy, suggesting the possible effects of a
chance imbalance among DES-treated patients, whichwas most pronounced in the EES subgroup, perhaps
related to the more frequent enrollment of subjects
with a history of cancer in this group. Third, bleeding
events, particularly those classiﬁed as GUSTO severe,
were numerically higher in the EES subgroup,
although variations in bleeding rates would not
necessarily be expected to truly differ between types
of stents.
Stent thrombosis rates, particularly beyond 1 year,
are low for currently used DES. Randomized trials
showing lower rates of stent thrombosis with newer
DES compared with ﬁrst-generation DES conﬁrm
that, in part, these lower rates are related to
improving stent technology over time (3–5,12). Our
ﬁndings in the EES-treated subset suggest that
the therapeutic window for beneﬁt (vs. risk) of
continued thienopyridine therapy may be narrow.
The number needed to treat to beneﬁt for stent
thrombosis was 235 over 18 months; the number
needed to treat to beneﬁt for MI was 98, and the
number needed to treat to harm for moderate or
severe bleeding was 84. Therefore, meticulous
assessment of bleeding risk should always affect
decisions regarding thienopyridine therapy dura-
tion. Overall treatment beneﬁt should be considered
according to the individual patient’s risk of events
and the effect of these events. Current data suggest
a net beneﬁt of continuation of therapy even with
small absolute reductions in stent thrombosis or
MI of w0.2%, an effect that was exceeded within
the EES subset of patients (13). Ongoing analyses
will delineate the individual predictors of the risk
and beneﬁt of late continuation of treatment as
well as the absolute effect of late ischemic and
PERSPECTIVES
WHAT IS KNOWN? Recent randomized trials and a meta-
analysis suggest that EES, the most commonly used stent type in
the DAPT study, are associated with lower rates of stent
thrombosis compared with paclitaxel-eluting stents.
WHAT IS NEW? In a post-hoc subset analysis of the DAPT
study in patients treated with EES, continued thienopyridine plus
placebo beyond 1 year was associated with reduced rates of stent
thrombosis and MI and increased rates of bleeding.
WHAT IS NEXT? This study contributes to the growing body of
evidence regarding prevention of stent thrombosis and MI after
coronary stenting with continued dual antiplatelet therapy, as
well as the risks of increased bleeding. Additional research is
needed to further individualize therapy to optimize patient
selection for continued thienopyridine therapy.
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147bleeding events on overall quantity and quality of
life.
STUDY LIMITATIONS. Speciﬁc limitations that apply
to comparisons of absolute event rates across DES
types in this study include the post-hoc nature of
the analysis, lack of randomization to DES type,
demographic differences between DES treatment
groups and smaller stent group sample sizes (lack of
power), and the limitations of multiple comparisons.
Additionally, despite the relatively large EES group
size, tests of interaction on randomized treatment
effect between stent groups remain underpowered.
Finally, false positives related to multiple testing may
also be present within these subgroup analyses.
CONCLUSIONS
Continued thienopyridine therapy beyond 1 year
following EES treatment is associated with signiﬁcant
reductions in risk of stent thrombosis or MI and an
increased risk of bleeding.
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